Rigel Pharmaceuticals Inc. (New)
$46.64
$0.79 (+1.72%)
$45.24Day Range$46.99
Key Statistics
Market Cap
$871.23M
Shares Outstanding
18.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 29, 2000
Round Lot
100
Locale
US
Trading Data
Day Open
$45.54
Day High
$46.99
Day Low
$45.24
Volume
939.6K
VWAP
$46.51
Prev Close
$45.85
Transactions
--
Acc. Volume
--
About Rigel Pharmaceuticals Inc. (New)
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
PHARMACEUTICAL PREPARATIONSSIC 2834174 employees611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080650-624-1100IPO Nov 29, 2000US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001034842
- Composite FIGI
- BBG000BPWTW7
- Share Class FIGI
- BBG001SD33Z0
- Ticker Root
- RIGL
- SIC Code
- 2834
About Rigel Pharmaceuticals Inc. (New) (RIGL) Stock
Rigel Pharmaceuticals Inc. (New) (RIGL) closed the 2026-09-18 session at $46.64, up 1.72% versus the previous close (+0.79). The stock opened at $45.54 and traded between $45.24 and $46.99 during that session. Session trading volume was 940K shares. The volume-weighted average price (VWAP) is $46.51.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Rigel Pharmaceuticals Inc. (New) has a market capitalization of $871.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RIGL is listed on the XNAS exchange. The company employs approximately 174 people. Rigel Pharmaceuticals Inc. (New) is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2000-11-29.
On this page you can find market RIGL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.